DOI:
10.1055/s-00034915
Onkologische Welt
LinksClose Window
References
Hamid O. et al.
5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001.
J Clin Oncol 2018;
36 (15) Abstract 9516.
We do not assume any responsibility for the contents of the web pages of other providers.